-
Prednisolone as a Mechanistic Control for ERAD Assays
2026-08-25
Prednisolone is a synthetic glucocorticoid that can clarify whether ERAD assay phenotypes reflect glucocorticoid receptor activity or targeted membrane-protein degradation. This article translates the ERADEC study into a practical framework for controls, interpretation, and experimental design.
-
Precision Cleavage for Nuclear Architecture
2026-08-25
How PreScission Protease and HRV 3C protease can strengthen recombinant protein workflows for mechanistic studies of Keap1–lamin signaling, chromatin organization, and translational research.
-
AMG 487: CXCR3 Antagonist Workflow
2026-08-24
AMG 487 provides a practical way to separate CXCR3-dependent chemokine signaling from downstream calcium flux, migration, macrophage polarization, and autophagy responses. This workflow translates reference-study findings into state-matched assays while addressing solubility, vehicle, metabolism, and interpretation risks.
-
Ruxolitinib–DRP1 Signaling in Anaplastic Thyroid Cancer
2026-08-24
The reference study identifies a mechanistic connection between JAK1/2–STAT3 signaling, DRP1-dependent mitochondrial fission, and two regulated cell-death programs in anaplastic thyroid carcinoma. Its in vitro and in vivo findings suggest that ruxolitinib suppresses STAT3 activity, reduces DRP1 transcription, and promotes caspase-dependent apoptosis together with GSDME-mediated pyroptosis.
-
Flumequine as a DNA Topoisomerase II Inhibitor
2026-08-23
Flumequine is a small-molecule DNA topoisomerase II inhibitor supplied for mechanistic research. Its reported approximately 15 μM inhibitory concentration supports assay development, but assay conditions and downstream cellular effects must be established experimentally.
-
Pyridostatin: A Structure-First Assay Strategy
2026-08-22
Pyridostatin TFA is more than a telomere probe: it can anchor structure-aware experiments spanning G-quadruplex DNA, cellular stress, and phenotype. This article explains how to interpret its results alongside emerging TDP-43 and RNA G-quadruplex biology without overstating the evidence.
-
BIIE 0246 in Y2R Signaling Research
2026-08-21
BIIE 0246 is a selective neuropeptide Y Y2 receptor antagonist for separating Y2R-dependent presynaptic, gut, feeding, and behavioral effects from Y1R-driven cardiac mechanisms. This practical guide connects receptor-selective pharmacology with coculture, slice, organ-bath, and behavioral workflows while emphasizing controls and translational limits.
-
MLN4924 HCl Salt: NAE Inhibition Workflows
2026-08-20
MLN4924 HCl salt provides a reversible way to interrogate NAE-dependent cullin-RING ligase activity, protein turnover, cell-cycle control, and inflammatory cell death. This practical guide connects pathway verification with assay design, viral inflammation research, and troubleshooting strategies that help distinguish on-target biology from general cytotoxicity.
-
TPPU (C5414) for Reliable sEH Assays
2026-08-20
TPPU (SKU C5414) provides a practical, data-supported approach for studying soluble epoxide hydrolase, fatty acid epoxide signaling, inflammatory pain, and osteoclastogenesis. This scenario-driven guide covers assay compatibility, stock preparation, interpretation, and evidence-based product selection without confusing biochemical potency with cellular efficacy.
-
Leptin (116-130), amide, mouse: Workflows
2026-08-19
Leptin (116-130), amide, mouse supports controlled studies of metabolic signaling, immune crosstalk, and leptin resistance without relying on an undefined biological mixture. This applied guide covers preparation, assay design, reference-informed pathway testing, and troubleshooting for obesity and diabetes research.
-
BMP4–GPX4 Protects RGCs in NMDA Glaucoma Models
2026-08-19
Fang and colleagues identify the BMP4–GPX4 axis as a potential regulator of ferroptosis and retinal stem cell performance in an NMDA-based mouse glaucoma model. Their findings connect reduced oxidative and iron stress in retinal ganglion cells with improved conditions for retinal stem cell survival and differentiation, while also highlighting important limits of translating an excitotoxic injury model to human glaucoma.
-
Nicotine Signaling and CKD Progression: Study Review
2026-08-18
Jain and Jaimes integrate clinical and experimental evidence showing that nicotine may accelerate chronic kidney disease through kidney-expressed nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and pro-fibrotic signaling. The review’s main practical contribution is a mechanistic framework for interpreting smoking-related renal injury and designing studies that distinguish nicotine effects from the broader toxicity of cigarette smoke.
-
Phosphatase Inhibitor Cocktail 2: Workflow Guide
2026-08-18
Phosphatase Inhibitor Cocktail 2 is a 100X aqueous reagent for protein phosphorylation preservation in crude extracts. Its broad formulation supports inhibition of tyrosine, acid, and alkaline phosphatases, while the cited liver-stress study shows why phosphoprotein handling matters for AMPK and p38 MAPK analysis.
-
c-Myc Tag Peptide: Mechanism and Use
2026-08-17
The c-Myc tag peptide A6003 is a synthetic C-terminal c-Myc fragment used for displacement of c-Myc-tagged fusion proteins from anti-c-Myc antibodies. Its defined molecular weight, high purity, solvent-specific solubility, and storage guidance support controlled immunoassay development rather than direct pharmacological inhibition of cellular MYC.
-
(5Z)-7-Oxozeaenol: Map TAK1 in Stress
2026-08-17
(5Z)-7-Oxozeaenol is a selective TAK1 inhibitor for separating inflammatory signaling from metabolic-stress adaptation. This guide connects TAK1-dependent p62 phosphorylation with AMPK–NRF2 feedback and translates that biology into more discriminating assay designs.